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Duchenne muscular dystrophy (DMD) is a severe, pro-
gressive muscle-wasting disorder, while Becker muscular
dystrophy (BMD) is milder muscle disease [1]. Both are
caused by mutations in dystrophin, a protein, which sta-
bilizes muscle fibers during contraction by linking mus-
cle actin to the extracellular matrix. In DMD patients
mutations disrupt the open reading frame, generating
prematurely truncated, nonfunctional dystrophins [2]. In
BMD patients, mutations maintain the reading frame
allowing production of internally deleted, partly func-
tional dystrophins.
The exon skipping approach uses antisense oligonucleo-
tides (AONs) to induce skipping of targeted exons during
pre-mRNA splicing, with the aim of reading frame restora-
tion, converting of the severe DMD into the milder BMD
phenotype [3]. This approach is mutation specific. How-
ever, as mutations cluster in a few hotspots, skipping of
some exons applies to larger groups of patients (e.g. exon
51 skipping applies to 13%) [4].
After promising results in cultured cells and animal
models where AON treatment allowed in dystrophin
restoration (reviewed in [3]), a first clinical trial was per-
formed by LUMC and Prosensa Therapeutics, where four
DMD patients where intramuscularly injected with an
exon 51 (GSK2402968/PRO051, a 2’-O-methyl phosphor-
othioate (2OMePS) AON) [5]. Exon skipping and dystro-
phin restoration was observed for each patient in muscle
biopsies taken 4 weeks after the injection.
Towards systemic application, studies in animal models
revealed that dystrophic muscles facilitated uptake of
2OMePS AONs and that subcutaneous delivery was feasi-
ble [6]. In a subsequent clinical trial, patients were subcu-
taneously injected with 2OMePS AONS targeting exon
51 [7]. Dystrophin was restored in a dose-dependent
manner at levels up to 15%. All patients were enrolled in
an open label extension study and have received subcuta-
neous AON injections at 6 mg/kg for over 2.5 years. A
pivotal, double-blind, placebo-controlled multicenter trial
for exon 51 skipping is currently ongoing (coordinated by
GlaxoSmithKline).
In parallel, preclinical studies to further optimise treat-
ment regimens are in progress as well as clinical trials for
additional exons for exon 44 skipping (PRO044, applicable
to 6% of patients). Trials are planned for exon 45 and 53
skipping (PRO045 and PRO053, both applicable to 8% of
patients).
The mutation specificity of the approach poses chal-
lenges to drug development regulations. A concerted effort
of academic researchers, industry, regulators and patients
is needed to adapt regulations to enable application of
these personalised medicine approaches to rare diseases.
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